» Articles » PMID: 20196788

Interferon Regulatory Factor-8 Modulates the Development of Tumour-induced CD11b+Gr-1+ Myeloid Cells

Overview
Journal J Cell Mol Med
Date 2010 Mar 4
PMID 20196788
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Tumour-induced myeloid-derived suppressor cells (MDSC) promote immune suppression and mediate tumour progression. However, the molecular basis for the generation of MDSC, which in mice co-express the CD11b(+) and Gr-1(+) cell surface markers remains unclear. Because CD11b(+)Gr-1(+) cells expand during progressive tumour growth, this suggests that tumour-induced events alter signalling pathways that affect normal myeloid cell development. Interferon regulatory factor-8 (IRF-8), a member of the IFN-gamma regulatory factor family, is essential for normal myelopoiesis. We therefore examined whether IRF-8 modulated tumour-induced CD11b(+)Gr-1(+) cell development or accumulation using both implantable (4T1) and transgenic (MMTV-PyMT) mouse models of mammary tumour growth. In the 4T1 model, both splenic and bone marrow-derived CD11b(+)Gr-1(+) cells of tumour-bearing mice displayed a marked reduction in IRF-8 expression compared to control populations. A causal link between IRF-8 expression and the emergence of tumour-induced CD11b(+)Gr-1(+) cells was explored in vivo using a double transgenic (dTg) mouse model designed to express transgenes for both IRF-8 and mammary carcinoma development. Despite the fact that tumour growth was unaffected, splenomegaly, as well as the frequencies and absolute numbers of CD11b(+)Gr-1(+) cells were significantly lower in dTg mice when compared with single transgenic tumour-bearing mice. Overall, these data reveal that IRF-8 plays an important role in tumour-induced development and/or accumulation of CD11b(+)Gr-1(+) cells, and establishes a molecular basis for the potential manipulation of these myeloid populations for cancer therapy.

Citing Articles

Partial Splenic Embolization for Portal Hypertension Exacerbation During Atezolizumab/Bevacizumab Combination Therapy in Unresectable Hepatocellular Carcinoma.

Ishikawa T, Terai N, Sato R, Natsui H, Iwasawa T, Ogawa M In Vivo. 2025; 39(2):936-941.

PMID: 40010973 PMC: 11884474. DOI: 10.21873/invivo.13898.


Interferon regulatory factor 8-driven reprogramming of the immune microenvironment enhances antitumor adaptive immunity and reduces immunosuppression in murine glioblastoma.

Montoya M, Collins S, Chuntova P, Patel T, Nejo T, Yamamichi A Neuro Oncol. 2024; 26(12):2272-2287.

PMID: 39115195 PMC: 11630541. DOI: 10.1093/neuonc/noae149.


IRF8-driven reprogramming of the immune microenvironment enhances anti-tumor adaptive immunity and reduces immunosuppression in murine glioblastoma.

Montoya M, Collins S, Chuntova P, Patel T, Nejo T, Yamamichi A bioRxiv. 2024; .

PMID: 38617245 PMC: 11014587. DOI: 10.1101/2024.04.02.587608.


Preoperative splenic area as a prognostic biomarker of early-stage non-small cell lung cancer.

Liu M, Yan G, Li Y, You R, Liu L, Zhang D Cancer Imaging. 2023; 23(1):116.

PMID: 38041154 PMC: 10691021. DOI: 10.1186/s40644-023-00640-0.


Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy.

Wu Y, Yi M, Niu M, Mei Q, Wu K Mol Cancer. 2022; 21(1):184.

PMID: 36163047 PMC: 9513992. DOI: 10.1186/s12943-022-01657-y.


References
1.
Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W . Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006; 203(12):2691-702. PMC: 2118163. DOI: 10.1084/jem.20061104. View

2.
Stewart T, Lutsiak M, Abrams S . Immune consequences of protracted host-tumor interactions in a transgenic mouse model of mammary carcinoma. Cancer Invest. 2008; 26(3):237-49. DOI: 10.1080/07357900701708419. View

3.
Nagaraj S, Gabrilovich D . Myeloid-derived suppressor cells. Adv Exp Med Biol. 2007; 601:213-23. DOI: 10.1007/978-0-387-72005-0_22. View

4.
Schmielau J, Finn O . Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 2001; 61(12):4756-60. View

5.
Suzuki E, Kapoor V, Jassar A, Kaiser L, Albelda S . Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005; 11(18):6713-21. DOI: 10.1158/1078-0432.CCR-05-0883. View